Preliminary results on tolerance and toxicity tests using human fibroblast interferon (beta-type) in patients with herpes genitalis infections.
A pilot placebo-controlled trial of human fibroblast interferon (beta 1-type) by local application in the treatment of genital herpes simplex virus infections was carried out in 10 young adults (2 men and 8 women). Patients received either placebo or human fibroblast interferon 3 times daily for 6 days; they were examined on at least seven occasions until healed and monthly thereafter. Preliminary observations suggest that human fibroblast interferon treatment as compared with placebo significantly reduced virus shedding, new lesion formation after 48 hours, and also the duration of genital lesions in both men and women. No toxicity was observed. The recurrence rates have been similar in placebo and human fibroblast interferon recipients.